CytomX Therapeutics (NASDAQ: CTMX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.360 | -0.370 | -0.0100 | ||||
REV | 20.660M | 17.136M | -3.524M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of CytomX Therapeutics (NASDAQ: CTMX) through any online brokerage.
Other companies in CytomX Therapeutics’s space includes: OncoCyte (NASDAQ:OCX), Ambrx Biopharma (NYSE:AMAM), Fusion Pharmaceuticals (NASDAQ:FUSN), Finch Therapeutics Group (NASDAQ:FNCH) and Gelesis Holdings (NYSE:GLS).
The latest price target for CytomX Therapeutics (NASDAQ: CTMX) was reported by BMO Capital on Friday, June 24, 2022. The analyst firm set a price target for 9.00 expecting CTMX to rise to within 12 months (a possible 373.68% upside). 5 analyst firms have reported ratings in the last year.
The stock price for CytomX Therapeutics (NASDAQ: CTMX) is $1.9 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for CytomX Therapeutics.
CytomX Therapeutics’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for CytomX Therapeutics.
CytomX Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.